Search
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalThe treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria. … Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Telmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigationalsmooth muscle, ultimately leading to a reduction in arterial blood pressure. … Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular
Mixtures: CO-TELSARIL 80/12,5, CO-TELSARIL 40/12,5Categories: Agents Acting on the Renin-Angiotensin SystemCeftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalCeftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. … [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy.
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt was developed by The Medicines Company (acquired by Novartis). … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections.
Palivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalHumanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). … Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[A33112] Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile of immunoglobulin antibodies to not undergo metabolism by liver enzymes, galcanezumab possesses … Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP).
Atractylodes lancea root oil
go.drugbank.com/drugs/DB14338ApprovedIt is not an approved drug.
Mixtures: OHUI White Extreme Illuminating Pact No.10, OHUI White Extreme Illuminating Pact No.10Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalReslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. … Studies demonstrated that reslizumab was not effective in various asthma outcomes in patients without eosinophilia [A31577]. Reslizumab was developed by Teva Pharmaceuticals.